Avacincaptad Pegol Ophthalmic Dosage

Medically reviewed by Drugs.com. Last updated on Nov 8, 2023.

Usual Adult Dose for Macular Degeneration

2 mg (0.1 mL of 20 mg/mL solution) by intravitreal injection to each affected eye once monthly. Can be given approximately every 28 days plus or minus 7 days.

Duration of therapy: Up to 12 months.

Comments:

• Before the intravitreal injection, check the intraocular pressure (IOP).
• If necessary, ocular hypotensive medicine can be administered to reduce IOP.

Use: For the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Precautions

CONTRAINDICATIONS:

• Ocular or periocular infections
• Active intraocular inflammation

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This drug should be administered by a qualified physician.
• Adequate anesthesia and topical microbicide should be given prior to intravitreal injection.
• Prior to use, allow the solution to reach room temperature.
• Each vial should only be used to treat a single eye.
• Do not use the filter needle for the intravitreal injection.
• Immediately inject the dose after its preparation.
• The manufacturer product information should be consulted.

Storage requirements:

• Store in the refrigerator at temperatures between 2C to 8C (36F to 46F).
• This drug may be kept at room temperature for up to 24 hours. Protect from light.
• Do not freeze. Do not shake.

Reconstitution/preparation techniques:

• Prepare the intravitreal injection aseptically.
• The manufacturer product information should be consulted.

Monitoring:
Ocular: Elevated intraocular pressure, neovascular AMD, optic nerve head perfusion

Patient advice:

• Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
• Instruct patients to report any symptoms suggestive of endophthalmitis (e.g., eye pain, redness of the eye, photophobia, blurring of vision) immediately.
• This drug may develop neovascular AMD, endophthalmitis, elevated intraocular pressure and retinal detachments.
• Patients may experience temporary visual disturbances and blurring after an intravitreal injection.
• Advise patients not to drive or use machinery until visual function has recovered sufficiently.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer